Delcath Systems, Inc. Expands Phase III Trial for Metastatic Melanoma to Florida

NEW YORK, NY--(Marketwire - July 24, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that Moffitt Cancer Center ("Moffitt"), a National Cancer Institute Comprehensive Cancer Center, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan. Moffitt is the seventh center in this multi-center trial using the Delcath System.